Get the Stockscreener App
272.05
1.37%
-3.79
Pre-market:
271.21
-0.84
-0.31%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $272.05, with a volume of 3.62M.
It is down -1.37% in the last 24 hours and down -2.93% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$275.84
Open:
$269.45
24h Volume:
3.62M
Relative Volume:
1.20
Market Cap:
$146.15B
Revenue:
$34.13B
Net Income/Loss:
$5.93B
P/E Ratio:
24.82
EPS:
10.96
Net Cash Flow:
$10.92B
1W Performance:
-4.13%
1M Performance:
-2.93%
6M Performance:
-16.36%
1Y Performance:
-11.47%
1-Day Range:
$266.02
$274.78
1-Week Range:
$266.02
$291.61
52-Week Range:
$253.30
$346.85
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
272.05 | 146.15B | 34.13B | 5.93B | 10.92B | 10.96 |
|
LLY
Lilly Eli Co
|
751.45 | 681.85B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.66 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
185.58 | 342.01B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
64.85 | 291.20B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.13 | 219.89B | 53.22B | 12.86B | 14.85B | 6.39 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Where are the Opportunities in (AMGN) - news.stocktradersdaily.com
Amgen Inc. (NASDAQ:AMGN) Holdings Decreased by Caisse DE Depot ET Placement DU Quebec - MarketBeat
Banque Transatlantique SA Invests $445,000 in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Alethea Capital Management LLC Takes Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Bayesian Capital Management LP Makes New Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
BNP Paribas Buys 2,122 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Aristotle Capital Management LLC Sells 16,789 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Accredited Wealth Management LLC Takes $847,000 Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen CEO Robert A. Bradway to Receive Honorary Degree from KGI - Eagle-Tribune
Amgen CEO Robert A. Bradway to Receive Honorary Degree from KGI - GlobeNewswire Inc.
38,090 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by Cutter Capital Management LP - MarketBeat
Capital Advantage Inc. Purchases New Shares in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Erste Group cuts Amgen stock rating to Hold from Buy - Investing.com
MHRA approves Amgen’s Tepezza for TED - The Pharma Letter
Amgen (AMGN) Downgraded by Analyst Due to Future Growth Concerns | AMGN Stock News - GuruFocus
MHRA approves Amgen’s Tepezza for NED - The Pharma Letter
Amgen Inc. (NASDAQ:AMGN) Stock Holdings Lessened by AQR Capital Management LLC - MarketBeat
Alteri Wealth LLC Purchases Shares of 11,903 Amgen Inc. (NASDAQ:AMGN) - MarketBeat
UK's MHRA Approves Amgen's Thyroid Eye Disease Treatment - marketscreener.com
Ameriprise Financial Inc. Has $527.09 Million Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Bridgefront Capital LLC Buys 3,103 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
BLI Banque de Luxembourg Investments Invests $2.20 Million in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Mercer Global Advisors Inc. ADV Acquires New Shares in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen's (AMGN) Tepezza Gains U.K. Approval for Thyroid Eye Disease - GuruFocus
Amgen Inc. (AMGN): A Bull Case Theory - Insider Monkey
Is Amgen Inc. (AMGN) the Best Dow Stock? - Yahoo Finance
Amgen wins U.K. nod for Tepezza in TED (AMGN:NASDAQ) - Seeking Alpha
What the Options Market Tells Us About Amgen - Nasdaq
Amgen (AMGN) Gains UK Approval for Tepezza in Thyroid Eye Disease Treatment | AMGN Stock News - GuruFocus
Amgen says MHRA granted marketing authorization to Tepezza for TED - TipRanks
Amgen’s TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom - Business Wire
The Best and Worst Dow Stocks - Insider Monkey
Forecasting The Future: 7 Analyst Projections For Amgen - Benzinga
Here's Why Amgen (AMGN) is a Strong Growth Stock - Yahoo Finance
Analyst Update: Amgen (AMGN) Price Target Raised to $280 by Mizuho | AMGN Stock News - GuruFocus
Amgen (AMGN) Price Target Increased by Mizuho Following Q1 Updat - GuruFocus
Captrust Financial Advisors Buys 10,753 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Brown Advisory Inc. - MarketBeat
Benjamin Edwards Inc. Raises Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Axa S.A. Sells 89,434 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Mizuho Raises Price Target on Amgen to $280 From $235 - marketscreener.com
Bellevue Group AG Grows Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen ploughing $900m into Ohio production site - BioProcess International
Here's Why Amgen (AMGN) is a Strong Value Stock - Yahoo
Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition - insights.citeline.com
Amgen: Waiting Patiently For A Real Catalyst - Seeking Alpha
Baird Financial Group Inc. Lowers Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Aptus Capital Advisors LLC Acquires 16,380 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
FY2025 EPS Estimates for Amgen Boosted by Cantor Fitzgerald - MarketBeat
Navigoe LLC Takes Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Voleon Capital Management LP Invests $1.52 Million in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):